Synthesis and radioiodination of selective ligands for the dopamine D3 receptor subtype

Bioorganic and Medicinal Chemistry Letters

Volumn 14, Issue 15, 2004, Pages 3963-3966

  Hocke, Carsten ^a   Prante, Olaf ^a   Löber, Stefan ^b   Hübner, Harald ^b   Gmeiner, Peter ^b   Kuwert, Torsten ^a  

^a Department of Nuclear Medicine ^*  (Germany)

^b UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

D3 receptor; Dopamine; Radioligand; SPET

Indexed keywords

BENZOFURAN DERIVATIVE; BENZOTHIOPHENE DERIVATIVE; DOPAMINE 2 RECEPTOR; DOPAMINE 3 RECEPTOR; PIPERAZINE DERIVATIVE; RECEPTOR SUBTYPE;

ARTICLE; DRUG SELECTIVITY; IMAGE ANALYSIS; LIGAND BINDING; RADIOCHEMISTRY; RADIOIODINATION; RECEPTOR AFFINITY; RECEPTOR BINDING; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SUBSTITUTION REACTION; SYNTHESIS;

INDICATORS AND REAGENTS; IODINE RADIOISOTOPES; KINETICS; LIGANDS; PIPERAZINES; RECEPTORS, DOPAMINE D2; RECEPTORS, DOPAMINE D3; THIOPHENES;

EID: 3042640431     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2004.05.052     Document Type: Article

References (17)

1. Sokoloff P., Giros B., Martres M.-P., Bouthenet M., Schwartz J.-C. Nature. 347:1990;146
2. Pilla M., Perachon S., Sautel F., Garrido F., Mann A., Wermuth C.G., Schwartz J.C., Sokoloff P. Nature. 400:1999;371
3. Bettinetti L., Schlotter K., Hübner H., Gmeiner P. J. Med. Chem. 45:2002;4594
4. Böckler F., Leng A., Mura A., Bettinetti L., Feldon J., Gmeiner P., Ferger B. Biochem. Pharmacol. 66:2003;1025
5. Prante O., Löber S., Hübner H., Gmeiner P., Kuwert T. J. Labelled Compd. Radiopharm. 44:2001;849
6. Owton W.-M. Tetrahedron Lett. 44:2003;7147
7. Bridges A.-J., Hammond A.-L., Maduakor E.-C., Schwartz C.-E. Tetrahedron Lett. 33:1992;7495
8. Dann O., Char H., Grießmeier H. Liebigs Ann. Chem. 1982;1836
9. Ono M., Kung M.P., Hou C., Kung H.F. Nucl. Med. Biol. 29:2002;633
10. 4), filtered, and concentrated to give 11a-f (12-45% yield)
11. 3, 360 MHz) 11a: δ (ppm): 1.7 (4H), 2.5 (2H), 2.7 (4H), 3.15 (4H), 3.55 (2H), 3.85 (3H), 6.8-7.0 (4H), 7.1 (1H), 7.25 (2H), 7.7 (1H), 8.05 (1H). Compound 11b: δ (ppm): 1.7 (4H), 2.5 (2H), 2.65 (4H), 3.1 (4H), 3.55 (2H), 6.95 (1H), 7.0 (1H), 7.15 (2H), 7.25 (1H), 7.5 (1H), 7.65 (1H), 8.0 (1H). Compound 11c: δ (ppm): 1.65 (4H), 2.45 (2H), 2.6 (4H), 3.05 (4H), 3.5 (2H), 3.65 (3H), 6.75-6.95 (4H), 7.0 (1H), 7.55 (1H), 7.65 (2H) 8.15 (1H). Compound 11d: δ (ppm): 1.65 (4H), 2.45 (2H), 2.6 (4H), 3.0 (4H), 3.5 (2H), 6.65 (2H), 7.1 (1H), 7.15 (1H), 7.5 (1H), 7.65 (2H), 8.15 (1H). Compound 11e: δ (ppm): 1.5 (4H), 2.3 (2H), 2.9 (4H), 3.2 (2H), 3.45 (4H), 3.75 (3H), 6.8-7.0 (4H), 7.4 (2H), 8.5 (1H). Compound 11f δ (ppm): 1.5 (4H), 2.35 (2H), 2.95 (4H), 3.2 (2H), 3.45 (4H), 7.1 (1H), 7.25 (2H), 7.35 (1H), 7.45 (1H), 8.55 (1H)
12. 131I] iodide (typically 2 MBq) and 10 μL hydrogen peroxide solution (30%) as oxidant at room temperature were added. After 2 min maximal RCY were observed to be 53-89% (radio-HPLC and radio-TLC) of substituted product, exclusively
13. 131I]11a-f were identified by reversed-phase chromatography (RP 18 Select B5 column (250 × 4 mm) eluted with methanol/aqueous buffer (70/30 v/v, 0.1 N ammonium formiate buffer, pH 6.8) and a flow rate of 1 mL/min). Analytical HPLC was performed on the following system: HPLC Hewlett Packard (HP 1100) with a quarternary pump and variable wavelength detector (HP 1100) connected to a radio-HPLC detector D505TR (Canberra Packard). Computer analysis of the HPLC data was performed using FLO-One software (Canberra Packard). Electronic autoradiography (InstantImager™, Canberra Packard) was used to analyse radio-TLC data
14. Hayes G., Biden T.J., Selbie L.A., Shine J. Mol. Endocrinol. 6:1992;920
15. Sokoloff P., Andrieux M., Besancon R., Pilon C., Martres M.-P., Giros B., Schwartz J.-C. Eur. J. Pharmacol. 225:1992;331
16. Asghari V., Sanyal S., Buchwaldt S., Paterson A., Jovanovic V., Van Tol H.-H.-M. J. Neurochem. 65:1995;115
17. Hübner H., Haubmann C., Utz W., Gmeiner P. J. Med. Chem. 43:2000;756